Spyre Therapeutics (SYRE) Stock: Buy, Sell, or Hold?
SYRE - Spyre Therapeutics, Inc. Common Stock
$92.33
-0.62 (-0.67%)
âŧ
5d:
+15.27%
30d:
+4.72%
90d:
-9.6%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 03, 2026
10d
Get Alerted When SYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SYRE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SYRE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SYRE is currently trading at $92.33, which is considered slightly high relative to its 30-day fair value range of $82.24 to $91.65.
Technical Outlook: Technically, SYRE is showing sideways momentum. Immediate support is located at $76.87, while resistance sits at $95.17.
Market Sentiment: SYRE scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $122.33 (+32.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SYRE is showing sideways momentum. Immediate support is located at $76.87, while resistance sits at $95.17.
Market Sentiment: SYRE scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $122.33 (+32.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$82.24 -
$91.65
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.5% below Wall St target ($122.33)
- WARNING: Composite score 38/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$82.24 -
$91.65
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$76.87
Resistance Level
$95.17
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.34
Wall Street Target
$122.33
(+32.5%)
Earnings Growth (YoY)
-99.7%
Share & Embed Analysis
Last updated: October 22, 2026 7:57 PM ET
Data refreshes hourly during market hours. Next update: 8:57 PM
Data refreshes hourly during market hours. Next update: 8:57 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 62 BUY |
|
REGN
Regeneron PharmaceuticalâĻ |
BUY
28 analysts |
$864 | 44 HOLD |
|
PRAX
Praxis Precision MedicinâĻ |
STRONG BUY
20 analysts |
$650 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 57 HOLD |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
STRONG BUY
20 analysts |
$31 | 66 BUY |
